|
 |
|
|||||||
|
|||||||||
Diabetes 51:3202-3210, 2002
© 2002 by the American Diabetes Association, Inc.
The Role of Autoimmunity in Islet Allograft Destruction
Major Histocompatibility Complex Class II Matching Is Necessary for Autoimmune Destruction of Allogeneic Islet Transplants After T-Cell Costimulatory Blockade
1 Laboratory of Immunogenetics and Transplantation, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
2 Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
3 Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
4 Nephrology Division, Children’s Hospital, Harvard Medical School, Boston, Massachusetts
Although it has often been assumed that transplanted allogeneic islets can be destroyed by recurrent autoimmunity in recipients with type 1 diabetes, definitive evidence is lacking and the settings in which this may occur have not been defined. To address these issues, we compared the survival of islet transplants (subject to tissue-specific autoimmunity) with cardiac transplants (not subject to tissue-specific autoimmunity) from various major histocompatibility complex (MHC)-matched and -mismatched donors transplanted into autoimmune NOD recipients. We found that when recipients were treated with combined B7 and CD154 T-cell costimulatory blockade, hearts survived best with better MHC matching, whereas islets survived worst when the donor and recipient shared MHC class II antigens. In the absence of full or MHC class II matching, there was no difference in the survival of islet and cardiac allografts. We also found that the tendency of NOD mice to resist tolerance induction by costimulation blockade is mediated by both CD4+ and CD8+ T-cells, not directly linked to the presence of autoimmunity, and conferred by non-MHC background genes. These findings have clinical importance because they suggest that under some circumstances, avoiding MHC class II sharing may provide better islet allograft survival in recipients with autoimmune diabetes, since mismatched allogeneic islets may be resistant to recurrent autoimmunity. Our results may have implications for the design of future clinical trials in islet transplantation.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. D. Salama, K. L. Womer, and M. H. Sayegh Clinical Transplantation Tolerance: Many Rivers to Cross J. Immunol., May 1, 2007; 178(9): 5419 - 5423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fiorina, M. Jurewicz, K. Tanaka, N. Behazin, A. Augello, A. Vergani, U. Von Adrian, N. R. Smith, M. H. Sayegh, and R. Abdi Characterization of Donor Dendritic Cells and Enhancement of Dendritic Cell Efflux With cc-Chemokine Ligand 21: A Novel Strategy to Prolong Islet Allograft Survival Diabetes, April 1, 2007; 56(4): 912 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Ford, B. H. Koehn, M. E. Wagener, W. Jiang, S. Gangappa, T. C. Pearson, and C. P. Larsen Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation J. Exp. Med., February 19, 2007; 204(2): 299 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Kupfer, M. L. Crawford, K. Pham, and R. G. Gill MHC-Mismatched Islet Allografts Are Vulnerable to Autoimmune Recognition In Vivo J. Immunol., August 15, 2005; 175(4): 2309 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamada, A. D. Salama, M. Sho, N. Najafian, T. Ito, J. P. Forman, R. Kewalramani, S. Sandner, H. Harada, M. R. Clarkson, et al. CD70 Signaling Is Critical for CD28-Independent CD8+ T Cell-Mediated Alloimmune Responses In Vivo J. Immunol., February 1, 2005; 174(3): 1357 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Shi, D. Wang, G. A. Hadley, A. W. Bingaman, S. T. Bartlett, and D. L. Farber Long-Term Islet Graft Survival in NOD Mice by Abrogation of Recurrent Autoimmunity Diabetes, September 1, 2004; 53(9): 2338 - 2345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pearson, P. Weiser, T. G. Markees, D. V. Serreze, L. S. Wicker, L. B. Peterson, A.-M. Cumisky, L. D. Shultz, J. P. Mordes, A. A. Rossini, et al. Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice Is Controlled by Allelic Variants of Idd3 Diabetes, August 1, 2004; 53(8): 1972 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Vu, F. Amanullah, Y. Li, G. Demirci, M. H. Sayegh, and X. C. Li Different Costimulatory and Growth Factor Requirements for CD4+ and CD8+ T Cell-Mediated Rejection J. Immunol., July 1, 2004; 173(1): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Nikolic, Y. Takeuchi, I. Leykin, Y. Fudaba, R. N. Smith, and M. Sykes Mixed Hematopoietic Chimerism Allows Cure of Autoimmune Diabetes Through Allogeneic Tolerance and Reversal of Autoimmunity Diabetes, February 1, 2004; 53(2): 376 - 383. [Abstract] [Full Text]
|
|
|
|
|
|
R. Abdi, T. K. Means, T. Ito, R. N. Smith, N. Najafian, M. Jurewicz, V. Tchipachvili, I. Charo, H. Auchincloss Jr., M. H. Sayegh, et al. Differential Role of CCR2 in Islet and Heart Allograft Rejection: Tissue Specificity of Chemokine/Chemokine Receptor Function In Vivo J. Immunol., January 15, 2004; 172(2): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Demirci, T. B. Strom, and X. C. Li Islet Allograft Rejection in Nonobese Diabetic Mice Involves the Common {gamma}-Chain and CD28/CD154-Dependent and -Independent Mechanisms J. Immunol., October 1, 2003; 171(7): 3878 - 3885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Makhlouf, A. Yamada, T. Ito, R. Abdi, M. J. I. Ansari, C. Q. Khuong, H. J. Winn, H. Auchincloss Jr., and M. H. Sayegh Allorecognition and Effector Pathways of Islet Allograft Rejection in Normal versus Nonobese Diabetic Mice J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2168 - 2175. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |